Otsuka Pharmaceutical Factory has reached an agreement with Mitsui & Co to acquire a remaining 20% interest in Otsuka Pharmaceutical India Private from the Mitsui.

The acquisition will make Otsuka Pharmaceutical India Private a wholly-owned subsidiary of Otsuka Pharmaceutical Factory.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In 2013, Otsuka Pharmaceutical Factory established Otsuka Pharmaceutical India Private as part of a joint venture (JV) with Claris Lifesciences (owning a 20% stake) and Mitsui (20%). The final 20% was owned by Claris, which was acquired by

“Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.”

Otsuka Pharmaceutical Factory acquired a 20% stake held by Claris in September 2017.

Mitsui is a diversified trading company based in Japan. Otsuka Pharmaceutical India Private provides intravenous and clinical nutrition products.

Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Shin Kowa Pharmaceutical produces NMN (ß nicotinamide mononucleotide). The firm expects the acquisition to enable it to build up the clinical trial results database of the Hiroshima University Graduate School of Biomedical & Health Sciences Project Research Center.